Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC
The Phase 3 KEYNOTE-D46/EVOKE-03 study of Trodelvy and KEYTRUDA has been discontinued due to lack of statistically significant efficacy.
Asset / Drug
Drug and asset intelligence for Trodelvy with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.